ATE496905T1 - Triazolyl-pyridyl-benzolsulfonamide als ccr2- oder ccr9-modulatoren zur behandlung von atherosklerose - Google Patents
Triazolyl-pyridyl-benzolsulfonamide als ccr2- oder ccr9-modulatoren zur behandlung von atheroskleroseInfo
- Publication number
- ATE496905T1 ATE496905T1 AT07810331T AT07810331T ATE496905T1 AT E496905 T1 ATE496905 T1 AT E496905T1 AT 07810331 T AT07810331 T AT 07810331T AT 07810331 T AT07810331 T AT 07810331T AT E496905 T1 ATE496905 T1 AT E496905T1
- Authority
- AT
- Austria
- Prior art keywords
- ccr2
- ccr9
- treatment
- benzenesulfonamides
- triazolyl
- Prior art date
Links
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 title abstract 4
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 title abstract 4
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 title abstract 4
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 title abstract 4
- 201000001320 Atherosclerosis Diseases 0.000 title 1
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 title 1
- 102100036303 C-C chemokine receptor type 9 Human genes 0.000 abstract 3
- 239000005557 antagonist Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 238000003556 assay Methods 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 102000004900 CC chemokine receptor 9 Human genes 0.000 abstract 1
- 108090001026 CC chemokine receptor 9 Proteins 0.000 abstract 1
- 102000004497 CCR2 Receptors Human genes 0.000 abstract 1
- 108010017312 CCR2 Receptors Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 125000004421 aryl sulphonamide group Chemical group 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83104206P | 2006-07-14 | 2006-07-14 | |
| US94585407P | 2007-06-22 | 2007-06-22 | |
| PCT/US2007/015786 WO2008008375A2 (en) | 2006-07-14 | 2007-07-10 | Triazolyl pyridyl benzenesulfonamides as ccr2 or ccr9 modulators for the treatment of inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE496905T1 true ATE496905T1 (de) | 2011-02-15 |
Family
ID=38670575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07810331T ATE496905T1 (de) | 2006-07-14 | 2007-07-10 | Triazolyl-pyridyl-benzolsulfonamide als ccr2- oder ccr9-modulatoren zur behandlung von atherosklerose |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7683176B2 (enExample) |
| EP (1) | EP2049515B1 (enExample) |
| JP (1) | JP5320291B2 (enExample) |
| CN (1) | CN101511800B (enExample) |
| AT (1) | ATE496905T1 (enExample) |
| AU (1) | AU2007272972B2 (enExample) |
| CA (1) | CA2657670C (enExample) |
| DE (1) | DE602007012261D1 (enExample) |
| ES (2) | ES2358618T3 (enExample) |
| WO (1) | WO2008008375A2 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1748989A2 (en) | 2004-05-12 | 2007-02-07 | ChemoCentryx Inc | Aryl sulfonamides |
| US7718683B2 (en) | 2006-07-14 | 2010-05-18 | Chemocentryx, Inc. | Triazolyl phenyl benzenesulfonamides |
| US7683176B2 (en) | 2006-07-14 | 2010-03-23 | Chemocentryx, Inc. | Triazolyl pyridyl benzenesulfonamides |
| US7776877B2 (en) | 2007-06-22 | 2010-08-17 | Chemocentryx, Inc. | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides |
| WO2009126675A1 (en) * | 2008-04-09 | 2009-10-15 | Boehringer Ingelheim International Gmbh | 2-sulfonylamino-4-heteroaryl butyramide antagonists of ccr10 |
| EP2598481B1 (en) | 2010-07-26 | 2016-08-31 | Bristol-Myers Squibb Company | Sulfonamide compounds useful as cyp17 inhibitors |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| KR20180059560A (ko) | 2010-10-29 | 2018-06-04 | 애브비 인코포레이티드 | 아폽토시스―유도제를 포함하는 고체 분산체 |
| US20140329809A1 (en) | 2011-10-28 | 2014-11-06 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| PT2953942T (pt) | 2013-02-06 | 2018-01-17 | Bayer Cropscience Ag | Derivados de pirazol substituídos com halogéneo como agentes pesticidas |
| JP6417415B2 (ja) | 2013-07-29 | 2018-11-07 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | １，３−二置換シクロペンタン誘導体 |
| ES2735360T3 (es) * | 2013-12-02 | 2019-12-18 | Chemocentryx Inc | Compuestos CCR6 |
| EP3087069B1 (en) | 2013-12-23 | 2019-01-30 | Norgine B.V. | Compounds useful as ccr9 modulators |
| EP3087074A1 (en) | 2013-12-23 | 2016-11-02 | Norgine BV | Benzene sulfonamides as ccr9 inhibitors |
| JP6556825B2 (ja) * | 2014-03-21 | 2019-08-07 | トビラ セラピューティクス， インコーポレイテッド | 線維症を処置するためのセニクリビロック |
| ES2971041T3 (es) | 2014-10-06 | 2024-06-03 | Chemocentryx Inc | Terapia combinada de inhibidores del receptor 9 de quimiocina C-C (CCR9) y anticuerpos bloqueadores anti-integrina alfa4beta7 para el tratamiento de la enfermedad inflamatoria intestinal |
| CN104341389A (zh) * | 2014-10-19 | 2015-02-11 | 湖南华腾制药有限公司 | 一种三唑哌啶盐酸盐的制备方法 |
| TN2017000483A1 (en) | 2015-05-20 | 2019-04-12 | Amgen Inc | Triazole agonists of the apj receptor. |
| US10000458B2 (en) * | 2016-03-31 | 2018-06-19 | Sumitomo Chemical Company, Limited | Production method of 1, 2, 4-triazole compound |
| WO2017192485A1 (en) | 2016-05-03 | 2017-11-09 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| RU2740902C2 (ru) * | 2016-06-03 | 2021-01-21 | Хемоцентрикс, Инк. | Способ лечения фиброза печени |
| TW201811766A (zh) | 2016-08-29 | 2018-04-01 | 瑞士商諾華公司 | N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途 |
| US10906890B2 (en) | 2016-11-16 | 2021-02-02 | Amgen Inc. | Triazole phenyl compounds as agonists of the APJ receptor |
| MA46827A (fr) | 2016-11-16 | 2019-09-25 | Amgen Inc | Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj |
| US11191762B2 (en) | 2016-11-16 | 2021-12-07 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the APJ Receptor |
| WO2018093580A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| EP3541792B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| WO2018097945A1 (en) | 2016-11-16 | 2018-05-31 | Amgen Inc. | Heteroaryl-substituted triazoles as apj receptor agonists |
| EP3551034A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| WO2018112264A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| TW201833108A (zh) | 2017-03-03 | 2018-09-16 | 大陸商江蘇豪森藥業集團有限公司 | 醯胺類衍生物抑制劑及其製備方法和應用 |
| GB201705263D0 (en) | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
| EP3655402A1 (de) | 2017-07-18 | 2020-05-27 | Bayer CropScience Aktiengesellschaft | Substituierte 3-heteroaryloxy-1h-pyrazole sowie deren salze und ihre verwendung als herbizide wirkstoffe |
| WO2019089335A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | Fused triazole agonists of the apj receptor |
| WO2019213006A1 (en) | 2018-05-01 | 2019-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
| JP2021534101A (ja) | 2018-08-09 | 2021-12-09 | ヴェルソー セラピューティクス， インコーポレイテッド | Ｃｃｒ２及びｃｓｆ１ｒを標的とするためのオリゴヌクレオチド組成物ならびにその使用 |
| AU2019383976B2 (en) | 2018-11-19 | 2025-07-03 | Bt Bidco, Inc. | Methods and devices for treating a disease with biotherapeutics |
| EP3996711A4 (en) | 2019-07-10 | 2023-08-16 | ChemoCentryx, Inc. | Indanes as pd-l1 inhibitors |
| US11866429B2 (en) | 2019-10-16 | 2024-01-09 | Chemocentryx, Inc. | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases |
| KR20220084119A (ko) | 2019-10-16 | 2022-06-21 | 케모센트릭스, 인크. | Pd-l1 질환의 치료를 위한 헤테로아릴-바이페닐 아미드 |
| US10792360B1 (en) | 2019-11-21 | 2020-10-06 | Chemocentryx, Inc. | Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies |
| US11707610B2 (en) | 2019-12-13 | 2023-07-25 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| CN115484944A (zh) | 2020-03-31 | 2022-12-16 | 坎莫森特里克斯公司 | 使用ccr9抑制剂和抗il-23阻断抗体治疗炎症性肠病的组合物和方法 |
| CN115477626B (zh) * | 2021-06-16 | 2024-08-02 | 上海璃道医药科技有限公司 | N-取代苯基磺酰胺类化合物及其用途 |
| CN118206536A (zh) * | 2022-12-15 | 2024-06-18 | 上海璃道医药科技有限公司 | N-取代苯基磺酰胺类化合物的固体形式 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0612247A1 (de) | 1991-11-15 | 1994-08-31 | Byk Gulden Lomberg Chemische Fabrik GmbH | Verwendung von sulfonylverbindungen |
| GB2361003A (en) | 2000-04-07 | 2001-10-10 | Astrazeneca Ab | Novel compounds |
| WO2001092437A1 (en) | 2000-06-01 | 2001-12-06 | Nippon Steel Chemical Co., Ltd. | Organic electroluminescent element material and organic electroluminescent element |
| CA2500492C (en) | 2002-11-18 | 2010-03-16 | Solomon Ungashe | Aryl sulfonamides |
| US20060111351A1 (en) | 2002-11-18 | 2006-05-25 | Solomon Ungashe | Aryl sulfonamides |
| US7227035B2 (en) | 2002-11-18 | 2007-06-05 | Chemocentryx | Bis-aryl sulfonamides |
| US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
| US20070021466A1 (en) | 2002-11-18 | 2007-01-25 | Solomon Ungashe | CCR2 inhibitors and methods of use thereof |
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| WO2005004818A2 (en) | 2003-07-09 | 2005-01-20 | Imclone Systems Incorporated | Heterocyclic compounds and their use as anticancer agents |
| JP4322062B2 (ja) * | 2003-07-23 | 2009-08-26 | 日本発條株式会社 | エンジンブロックおよびその製造方法 |
| KR100955170B1 (ko) | 2004-03-03 | 2010-04-29 | 키모토 컴파니 리미티드 | 광제어 필름 및 그것을 사용한 백라이트 장치 |
| EP1748989A2 (en) | 2004-05-12 | 2007-02-07 | ChemoCentryx Inc | Aryl sulfonamides |
| ATE503741T1 (de) | 2005-01-14 | 2011-04-15 | Chemocentryx Inc | Heteroarylsulfonamide und ccr2 |
| US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| WO2007014054A2 (en) | 2005-07-22 | 2007-02-01 | Glaxo Group Limted | Benzenesulfonamide inhibitor of ccr2 chemokine receptor |
| WO2007014008A2 (en) | 2005-07-22 | 2007-02-01 | Glaxo Group Limted | Benzenesulfonamide inhibitor of ccr2 chemokine receptor |
| WO2008008374A2 (en) | 2006-07-14 | 2008-01-17 | Chemocentryx, Inc. | Ccr2 inhibitors and methods of use thereof |
| US7718683B2 (en) | 2006-07-14 | 2010-05-18 | Chemocentryx, Inc. | Triazolyl phenyl benzenesulfonamides |
| WO2008010934A2 (en) | 2006-07-14 | 2008-01-24 | Chemocentryx, Inc. | Triazolyl phenyl benzenesulfonamides |
| US7683176B2 (en) | 2006-07-14 | 2010-03-23 | Chemocentryx, Inc. | Triazolyl pyridyl benzenesulfonamides |
-
2007
- 2007-07-10 US US11/775,601 patent/US7683176B2/en active Active
- 2007-07-10 ES ES07810331T patent/ES2358618T3/es active Active
- 2007-07-10 CA CA2657670A patent/CA2657670C/en active Active
- 2007-07-10 EP EP07810331A patent/EP2049515B1/en active Active
- 2007-07-10 AT AT07810331T patent/ATE496905T1/de not_active IP Right Cessation
- 2007-07-10 CN CN200780033360XA patent/CN101511800B/zh active Active
- 2007-07-10 AU AU2007272972A patent/AU2007272972B2/en active Active
- 2007-07-10 ES ES07836049T patent/ES2360741T3/es active Active
- 2007-07-10 DE DE602007012261T patent/DE602007012261D1/de active Active
- 2007-07-10 JP JP2009520761A patent/JP5320291B2/ja active Active
- 2007-07-10 WO PCT/US2007/015786 patent/WO2008008375A2/en not_active Ceased
-
2010
- 2010-02-19 US US12/708,900 patent/US8445518B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN101511800A (zh) | 2009-08-19 |
| US7683176B2 (en) | 2010-03-23 |
| AU2007272972B2 (en) | 2011-12-01 |
| CA2657670A1 (en) | 2008-01-17 |
| WO2008008375A3 (en) | 2008-03-06 |
| US20080039504A1 (en) | 2008-02-14 |
| JP5320291B2 (ja) | 2013-10-23 |
| US8445518B2 (en) | 2013-05-21 |
| HK1131134A1 (en) | 2010-01-15 |
| US20100152186A1 (en) | 2010-06-17 |
| ES2360741T3 (es) | 2011-06-08 |
| EP2049515A2 (en) | 2009-04-22 |
| ES2358618T3 (es) | 2011-05-12 |
| CN101511800B (zh) | 2013-02-27 |
| CA2657670C (en) | 2012-04-17 |
| AU2007272972A1 (en) | 2008-01-17 |
| DE602007012261D1 (de) | 2011-03-10 |
| JP2010504280A (ja) | 2010-02-12 |
| EP2049515B1 (en) | 2011-01-26 |
| WO2008008375A2 (en) | 2008-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE496905T1 (de) | Triazolyl-pyridyl-benzolsulfonamide als ccr2- oder ccr9-modulatoren zur behandlung von atherosklerose | |
| ATE498615T1 (de) | Triazolylphenylbenzensulfonamide | |
| ATE548039T1 (de) | Kondensierte heteroarylpyridyl- und phenylbenzensulfonamide als ccr2-modulatoren zur behandlung von entzündungen | |
| WO2008008374A3 (en) | Ccr2 inhibitors and methods of use thereof | |
| MX2007008474A (es) | Sulfonamidas de heteroarilo y ccr2. | |
| ATE438401T1 (de) | 1-aryl-4-substituierte piperazin-derivate zur verwendung als ccr1-antagonisten zur behandlung von entzündungen und immunerkrankungen | |
| DK1798223T3 (da) | Arylsulfonamider | |
| MX372722B (es) | Sulfonamidas de aza-aril 1h-pirazol-1-il benceno | |
| EA200901583A1 (ru) | N-(2-(гетарил)арил)арилсульфонамиды и n-(2-(гетарил)гетарил)арилсульфонамиды | |
| EP2155203A4 (en) | Azaindazole compounds and methods of use | |
| ATE465150T1 (de) | Für die behandlung von durch den gpr38-rezeptor vermittelten krankheiten geeignete piperazinylderivate | |
| ATE505468T1 (de) | N-gebundene heterocyclische antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden | |
| ATE469173T1 (de) | Pegyliertes pth als pth-rezeptormodulatoren und ihre verwendung | |
| ATE481392T1 (de) | Benzimidazolderivate zur behandlung entzündlicher erkrankungen | |
| DE602005026699D1 (de) | Vorrichtung zur behandlung von hauterkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |